BeStock  
Stocks › Biotechnology › CLYM

Climb Bio CLYM

US equityMarket cap rank #3548Biotechnology
$9.19 −$0.09 (-0.97%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.03 -1.76%
Open$8.98
Prev close$9.28
Day range$8.90 – $9.40
Volume770.2K
Market cap$539.80M
P/E (TTM)–
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

CLYM at a glance

Climb Bio (CLYM) is trading at $9.19, down 0.97% on the day. Its market value of $539.80M makes it the 3548th largest of the 3753 companies we follow.

Over a full year the shares have ranged across $1.64 to $18.33, which puts the current price roughly 45% of the way up that band. Holders are ahead 440.6% over twelve months, but down 44.0% across the last three months.

On the chart it has slipped under both the 50-day ($11.01) and 200-day ($10.79) moving averages; RSI is 41, and the last 30 sessions moved at roughly 103% annualized volatility.

Revenue for the quarter ended Sep 2026 was $0.00, and a net loss of $14.57M.

12 analysts follow the stock and the average call is "buy". The mean target, $29.18, sits 217.5% over where the stock trades.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

Key statistics

Bid / Ask$8.88 / $10.25
Average price today$9.19
Volume770.2KAvg (90d) 1.31M
Turnover$7.08M
Turnover rate2.09%of shares outstanding
Volume ratio1.14vs. recent average pace
Day amplitude5.37%
Market cap$539.80M
Float market cap$339.13M
Shares outstanding36.90M
EPS (TTM)-$0.88
P/B2.37
Book value / share$3.88
Net profit (TTM)-$51.69M
Net assets$228.08M
30-day volatility102.8%annualized
Avg daily range (ATR)10.36%of price, 14 days
Max drawdown (1y)-50.6%-48.5% from 1y peak

Quote as of Nov 20, 2026 8:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.

BeStock Grade

C
BeStock Grade

Composite of 3 factors below, ranked against the 3734 U.S. stocks BeStock covers.

B
Valuation

Cheaper than usual on its own 5-year P/E history scores higher.

F
Momentum

Trading closer to its 52-week high than most peers scores higher.

B
Wall Street

12 analysts, consensus Buy.

How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.

Six-factor research snapshot

Overall percentile: 54.5 · 2026-11-22 14:27 UTC. Higher values indicate a stronger relative ranking.

FactorPercentile
Valuation—
Growth—
Profitability5.7
Momentum34.1
Financial health99.7
Analyst view97.3

Price forecast

What Wall Street analysts and Morningstar's fair-value model expect for the stock

Analyst price target (avg)$29.18+217.5% vs. current price
Consensus ratingBuy12 analysts covering
Morningstar fair value$12.49Price is below fair value

Wall Street’s average 12-month target is $29.18, 217.5% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $12.49, so shares trade 26.4% below that estimate. On earnings multiple, it sits in the 25th percentile of its own five-year valuation range (cheaper than usual).

Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
-1.0%
1 week
-11.3%
1 month
-12.8%
3 months
-44.0%
6 months
-16.5%
Year to date
+129.8%
1 year
+440.6%
Day range
$8.90$9.40
52-week range
$1.64$18.33

Technical signals

Full technicals →
Trend readStrong downtrend

1 bullish · 6 bearish of 7 signals

IndicatorValueSignal
Price vs 20-day average-8.5%Bearish
Price vs 50-day average-16.6%Bearish
Price vs 200-day average-14.8%Bearish
50-day vs 200-day50d above 200dBullish
RSI (14)40.5Bearish
MACD (12,26,9)-0.37Bearish
Bollinger band position26%Bearish

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

How CLYM ranks on BeStock

Market value#3530 of 3734
Closeness to 52-week high#3035 of 3724
Dollar volume today#2565 of 3734

Ranks are among the 3,734 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.

CLYM is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.

Since 2020-12-28, the strategy has returned 401.7% (183.6% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.

Strategy Backtest

Pick a strategy above and run the backtest to see its simulated performance on CLYM.

Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.

Community Sentiment on CLYM

No votes yet — be the first to weigh in.

Reader sentiment, not investment advice. One vote per visitor; click again to change it.

CLYM stock: common questions

What is CLYM's latest share price?

$9.19 is the latest print for CLYM, a move of -0.97% against yesterday's close of $9.28. Today's low and high so far: $8.90 and $9.40.

How large is Climb Bio by market value?

Equity value comes to $539.80M at the current price. By that measure it is number 3548 of the 3753 names in our coverage.

Is CLYM near its 52-week high or low?

The year's floor is $1.64 and the ceiling $18.33. Shares are 49.9% away from that ceiling.

Does Climb Bio pay a dividend?

Our data shows no dividend paid by Climb Bio over the trailing twelve months.

Is CLYM rated a buy by Wall Street?

Of 12 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $29.18, with the most cautious at $23.00 and the most optimistic at $40.00.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Discussion

No comments yet — be the first to weigh in on CLYM.

Sign in to join the discussion.

Scroll to Top